Danske Bank A S Has $225,000 Stock Position in Medpace Holdings, Inc. $MEDP

Danske Bank A S reduced its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 84.7% during the 4th quarter, Holdings Channel reports. The fund owned 400 shares of the company’s stock after selling 2,220 shares during the period. Danske Bank A S’s holdings in Medpace were worth $225,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently bought and sold shares of MEDP. Quent Capital LLC acquired a new position in shares of Medpace in the third quarter valued at approximately $25,000. Optiver Holding B.V. bought a new position in shares of Medpace during the third quarter worth approximately $27,000. Steigerwald Gordon & Koch Inc. acquired a new stake in Medpace during the 4th quarter worth approximately $30,000. Quarry LP bought a new stake in Medpace in the 3rd quarter valued at $35,000. Finally, Root Financial Partners LLC bought a new stake in Medpace in the 3rd quarter valued at $38,000. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Key Medpace News

Here are the key news stories impacting Medpace this week:

• Neutral Sentiment: Multiple plaintiff law firms have issued investor alerts reminding shareholders of a June 8, 2026 lead‑plaintiff deadline and soliciting clients — increasing public attention and potential litigation coordination. ROSEN investor alert
• Negative Sentiment: A securities‑fraud class action alleges Medpace understated cancellation rates and overstated its book‑to‑bill, linking those claims to a reported ~16% single‑day stock decline — a headline risk that can pressure investor sentiment and valuation. BFA Law class action alert
• Negative Sentiment: Levi & Korsinsky and other firms specifically allege senior executives (naming the company president) were involved in misleading disclosures; naming executives raises reputational and governance risk that can prolong selling pressure. Levi & Korsinsky alert
• Negative Sentiment: Analyst commentary and research notes cited in filings (e.g., a Baird note and a Truist price‑target reduction) are being used in the litigation narrative and may reinforce negative sentiment among institutional holders. Analyst commentary referenced in alerts

Analyst Ratings Changes

Several research analysts have weighed in on the company. Wall Street Zen cut Medpace from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. Truist Financial reduced their target price on shares of Medpace from $555.00 to $539.00 and set a “hold” rating for the company in a research report on Wednesday, February 11th. Jefferies Financial Group raised shares of Medpace from a “hold” rating to a “buy” rating and set a $560.00 price target on the stock in a research report on Friday, February 13th. Robert W. Baird dropped their price objective on shares of Medpace from $565.00 to $477.00 and set an “outperform” rating for the company in a research note on Friday, April 24th. Finally, Mizuho set a $582.00 price objective on shares of Medpace in a report on Wednesday, February 11th. Four research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Medpace presently has an average rating of “Hold” and an average price target of $467.08.

Medpace Price Performance

Shares of NASDAQ MEDP opened at $426.79 on Thursday. The business has a fifty day moving average price of $468.07 and a two-hundred day moving average price of $531.70. The stock has a market capitalization of $12.19 billion, a PE ratio of 26.83, a P/E/G ratio of 2.18 and a beta of 1.19. Medpace Holdings, Inc. has a fifty-two week low of $284.48 and a fifty-two week high of $628.92.

Medpace (NASDAQ:MEDP) last released its earnings results on Wednesday, April 22nd. The company reported $4.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.74 by $0.54. The company had revenue of $706.60 million for the quarter, compared to analyst estimates of $697.82 million. Medpace had a return on equity of 120.89% and a net margin of 17.19%.Medpace’s quarterly revenue was up 26.5% on a year-over-year basis. During the same period in the prior year, the firm posted $3.67 EPS. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. On average, equities analysts expect that Medpace Holdings, Inc. will post 17.04 EPS for the current year.

Insider Buying and Selling

In other Medpace news, President Jesse J. Geiger sold 31,707 shares of the firm’s stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $455.30, for a total value of $14,436,197.10. Following the transaction, the president directly owned 15,000 shares of the company’s stock, valued at $6,829,500. This trade represents a 67.88% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 20.50% of the stock is currently owned by corporate insiders.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.